(Q40414210)

20 September 2017

title

Antiangiogenic treatment with endostatin inhibits progression of AML in vivo (English)

1 reference

20 September 2017

main subject

angiogenesis inhibitor

1 reference

Schuch G

1

1 reference

20 September 2017

Oliveira-Ferrer L

2

1 reference

20 September 2017

Loges S

3

1 reference

20 September 2017

Laack E

4

1 reference

20 September 2017

Bokemeyer C

5

1 reference

20 September 2017

Hossfeld DK

6

1 reference

20 September 2017

Fiedler W

7

1 reference

20 September 2017

Ergun S

8

1 reference

20 September 2017

publication date

1 August 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

19

1 reference

20 September 2017

issue

8

1 reference

20 September 2017

page(s)

1312-1317

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403824

20 September 2017

exact match

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Local endostatin treatment of gliomas administered by microencapsulated producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Endostatin's antiangiogenic signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Endostatin induces endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403824

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403824

1 reference

Dimensions Publication ID

20 September 2017

1039877664

0 references

1 reference